- Home
- RENB vs CLYM Comparison
RENB vs CLYM Comparison
Compare RENB & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- CLYM
- Stock Information
- Founded
- RENB 2011
- CLYM 2018
- Country
- RENB United States
- CLYM United States
- Employees
- RENB N/A
- CLYM N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- RENB Health Care
- CLYM
- Exchange
- RENB Nasdaq
- CLYM NYSE
- Market Cap
- RENB 121.3M
- CLYM 101.6M
- IPO Year
- RENB N/A
- CLYM 2021
- Fundamental
- Price
- RENB $0.54
- CLYM $1.22
- Analyst Decision
- RENB
- CLYM
- Analyst Count
- RENB 0
- CLYM 0
- Target Price
- RENB N/A
- CLYM N/A
- AVG Volume (30 Days)
- RENB 552.0K
- CLYM 172.8K
- Earning Date
- RENB 05-14-2025
- CLYM 03-25-2025
- Dividend Yield
- RENB N/A
- CLYM N/A
- EPS Growth
- RENB N/A
- CLYM N/A
- EPS
- RENB N/A
- CLYM N/A
- Revenue
- RENB N/A
- CLYM N/A
- Revenue This Year
- RENB N/A
- CLYM N/A
- Revenue Next Year
- RENB N/A
- CLYM N/A
- P/E Ratio
- RENB N/A
- CLYM N/A
- Revenue Growth
- RENB N/A
- CLYM N/A
- 52 Week Low
- RENB $0.40
- CLYM $1.20
- 52 Week High
- RENB $3.05
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- RENB 31.60
- CLYM N/A
- Support Level
- RENB $0.63
- CLYM N/A
- Resistance Level
- RENB $0.73
- CLYM N/A
- Average True Range (ATR)
- RENB 0.07
- CLYM 0.00
- MACD
- RENB -0.02
- CLYM 0.00
- Stochastic Oscillator
- RENB 0.00
- CLYM 0.00
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.